Wuxi Biologics (Cayman) (1FW2) Price & Analysis

4 Followers

1FW2 Stock Chart & Stats

€4.34

-€0.01(-0.23%)

At close: Jul 24 4:00 PM EDT

€4.34

-€0.01(-0.23%)

Day’s Range― - ―

52-Week Range€3.16 - €4.68

Previous CloseN/A

Volume0.00

Average Volume (3M)1.95K

Market Cap

€17.75B

Enterprise Value€123.38K

Total Cash (Recent Filing)€15.74B

Total Debt (Recent Filing)€3.11B

Price to Earnings (P/E)28.0

Beta0.88

Next Earnings

Aug 25, 2026

EPS Estimate

0.06

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)1.19

Shares Outstanding4,143,562,500

10 Day Avg. Volume2,439

30 Day Avg. Volume1,954

Financial Highlights & Ratios

PEG Ratio0.53

Price to Book (P/B)2.53

Price to Sales (P/S)5.48

P/FCF Ratio42.67

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€5.56

Price Target Upside28.05% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering8

EPS Forecast (FY)0.14

Revenue Forecast (FY)€2.80B

Bulls Say, Bears Say

Bulls Say

High Profitability MarginsSustained high gross and operating margins indicate structural cost efficiency and pricing power in Wuxi's CRDMO model. Healthy margins provide durable internal funding for capacity, R&D and customer support, cushioning the business through slow top-line periods and supporting long-term returns.

Conservative Balance SheetVery low and falling leverage gives the company flexibility to invest in capital-intensive manufacturing capacity and weather industry cycles without large refinancing risk. A strong equity base supports capital allocation optionality and reduces solvency risk over the medium term.

Integrated End-to-end CRDMO PlatformAn integrated service offering across cell line, process development, analytics and commercial manufacturing fosters client consolidation and program stickiness. This breadth creates recurring revenue as assets progress to commercial supply, improving long-term revenue visibility and client relationship durability.

Bears Say

Slowing Revenue GrowthA marked slowdown in top-line growth reduces capacity utilization and delays the maturation of higher-margin commercial manufacturing revenues. For a CRDMO, slower program progression materially affects multi-year revenue visibility and can weaken operating leverage and return on invested capital.

Weaker Cash Conversion And Volatile FCFLower FCF conversion and historical negative free cash flow reflect cash volatility from capex and working capital. This limits the firm's ability to self-fund expansion consistently, raising the likelihood of external financing for large capacity projects and constraining predictable capital returns.

Margins Below Prior PeaksEarnings margins falling from earlier peaks suggests competitive pricing pressure, mix shifts or cost inflation. If sustained, this reduces the firm’s excess profitability cushion, limits reinvestment capacity and heightens sensitivity to revenue softness in a capital-intensive manufacturing business.

Wuxi Biologics (Cayman) News

WuXi Biologics sets August board meeting to approve interim 2026 results

Wuxi Biologics (Cayman) ( ($HK:2269) ) has shared an update. WuXi Biologics (Cayman) Inc. has scheduled a board...

12d ago

WuXi Biologics Wins Full Shareholder Backing at 2026 AGM

Wuxi Biologics (Cayman) ( ($HK:2269) ) has provided an update. WuXi Biologics said shareholders approved all resolutions at...

2M ago

Wuxi Biologics Grants Time-Based Restricted Shares to 21 Employees

Wuxi Biologics (Cayman) ( ($HK:2269) ) has issued an update. Wuxi Biologics has approved the grant of 288,441...

2M ago

WuXi Biologics Schedules 2026 Business Update Calls for Investors

Wuxi Biologics (Cayman) ( ($HK:2269) ) just unveiled an update. WuXi Biologics has announced that it will host...

2M ago

WuXi Biologics Launches US$400 Million Share Buyback Plan

Wuxi Biologics (Cayman) ( ($HK:2269) ) just unveiled an update. WuXi Biologics has resolved to activate its shareholder-approved...

2M ago

WuXi Biologics Sets 2026 AGM to Vote on Board, Auditors and New Share Mandate

The latest update is out from Wuxi Biologics (Cayman) ( ($HK:2269) ). WuXi Biologics (Cayman) Inc. has called...

3M ago

WuXi Biologics: Robust Backlog, High-Margin Growth Drivers, and Capacity Expansion Underpin Buy Rating

CMB International Securities analyst Jill Wu maintained a Buy rating on Wuxi Biologics (Cayman) today and set a...

4M ago

Wuxi Biologics Grants 25.6 Million Restricted Shares Under Incentive Scheme

Wuxi Biologics (Cayman) ( ($HK:2269) ) has issued an update. Wuxi Biologics has approved the grant of 25,575,356...

4M ago

WuXi Biologics Schedules Briefings on 2025 Annual Results for Global Investors

Wuxi Biologics (Cayman) ( ($HK:2269) ) just unveiled an announcement. WuXi Biologics (Cayman) Inc., a Hong Kong-listed biologics...

4M ago

Wuxi Biologics Delivers Strong 2025 Profit Growth as Project Portfolio Expands

Wuxi Biologics (Cayman) ( ($HK:2269) ) has provided an announcement. Wuxi Biologics reported strong 2025 results, with revenue...

4M ago

WuXi Biologics downgraded to Neutral from Buy at Goldman Sachs

Goldman Sachs downgraded WuXi Biologics to Neutral from Buy with a price target of HK$21.60, down from HK$50....

2y ago

GSK, WuXi Biologics enter into license agreement on TCE antibodies

WuXi Biologics (WXIBF) announced a license agreement with GSK plc (GSK) under which GSK will have exclusive licenses...

4y ago

GSK

1FW2 FAQ

What was Wuxi Biologics (Cayman) Inc.’s price range in the past 12 months?

Wuxi Biologics (Cayman) Inc. lowest stock price was €3.16 and its highest was €4.68 in the past 12 months.

What is Wuxi Biologics (Cayman) Inc.’s market cap?

Wuxi Biologics (Cayman) Inc.’s market cap is €17.75B.

When is Wuxi Biologics (Cayman) Inc.’s upcoming earnings report date?

Wuxi Biologics (Cayman) Inc.’s upcoming earnings report date is Aug 25, 2026 which is in 20 days.

How were Wuxi Biologics (Cayman) Inc.’s earnings last quarter?

Wuxi Biologics (Cayman) Inc. released its earnings results on Mar 24, 2026. The company reported €0.075 earnings per share for the quarter, missing the consensus estimate of €0.081 by -€0.006.

Is Wuxi Biologics (Cayman) Inc. overvalued?

According to Wall Street analysts Wuxi Biologics (Cayman) Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Wuxi Biologics (Cayman) Inc. pay dividends?

Wuxi Biologics (Cayman) Inc. does not currently pay dividends.

What is Wuxi Biologics (Cayman) Inc.’s EPS estimate?

Wuxi Biologics (Cayman) Inc.’s EPS estimate is 0.06.

How many shares outstanding does Wuxi Biologics (Cayman) Inc. have?

Wuxi Biologics (Cayman) Inc. has 4,143,562,500 shares outstanding.

What happened to Wuxi Biologics (Cayman) Inc.’s price movement after its last earnings report?

Wuxi Biologics (Cayman) Inc. reported an EPS of €0.075 in its last earnings report, missing expectations of €0.081. Following the earnings report the stock price went up 4.784%.

Which hedge fund is a major shareholder of Wuxi Biologics (Cayman) Inc.?

Currently, no hedge funds are holding shares in DE:1FW2

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Wuxi Biologics (Cayman) Stock Smart Score

Outperform

Analyst Consensus

Strong Buy

Average Price Target:
€5.56 (28.05% Upside)

Technicals

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

16.77%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Wuxi Biologics (Cayman) Inc.

Headquartered in Wuxi, China, and established in 2014, WuXi Biologics (Cayman) Inc. delivers a comprehensive, integrated suite of services spanning the entire biologics lifecycle, from initial discovery through development to large-scale manufacturing. The company's operations have a global footprint, serving clients across the People's Republic of China, North America, Europe, and other international regions. Its diversified offerings also include specialized consultation in biopharmaceutical technology, international sales contracting, the development and deployment of advanced testing methodologies, and robust marketing and sales support. Furthermore, WuXi Biologics is involved in providing dedicated biologics clinical and manufacturing services, the production and distribution of various medical products, contract development and manufacturing (CDMO) for vaccines and associated businesses, and acting as a supplier of key materials. The firm maintains strategic partnerships with notable entities such as ImmuneOncia Therapeutics, Legochem Biosciences Inc., Worg Pharma, OncoC4, and Exelixis Inc.

Wuxi Biologics (Cayman) (1FW2) Earnings & Revenues

Historic Earnings Reports

1FW2 Company Deck

1FW2 Earnings Call

Q4 2026

0:00 / 0:00

1FW2 Stock 12 Month Forecast

Average Price Target

€5.56

▲(28.05% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"€2","7":"€7","3.25":"€3.25","4.5":"€4.5","5.75":"€5.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":6.036565670000001,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€6.04</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.557290716250001,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€5.56</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.2068010000000005,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€5.21</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,3.25,4.5,5.75,7],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.22,4.359735820769231,4.499471641538461,4.639207462307692,4.778943283076924,4.918679103846154,5.058414924615385,5.198150745384615,5.337886566153847,5.477622386923077,5.617358207692308,5.757094028461539,5.89682984923077,{"y":6.036565670000001,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.22,4.322868516634615,4.425737033269231,4.528605549903846,4.631474066538462,4.734342583173077,4.837211099807693,4.940079616442308,5.042948133076924,5.145816649711539,5.248685166346155,5.35155368298077,5.454422199615385,{"y":5.557290716250001,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.22,4.2959077692307694,4.371815538461538,4.447723307692308,4.523631076923077,4.5995388461538464,4.675446615384615,4.751354384615385,4.827262153846154,4.9031699230769235,4.979077692307692,5.054985461538462,5.130893230769231,{"y":5.2068010000000005,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.329,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.833,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.414,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.01,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.5,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.465,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.81,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.208,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.82,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.58,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.75,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.81,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.22,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >